Krsnaa Diagnostics Limited has informed the Exchange about General Updates
KRSNAA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Krsnaa Diagnostics reported standalone PAT of ₹1,026.75 million for FY26, up 24% from ₹828.08 million in FY25. Consolidated PAT stood at ₹1,014.31 million, up 30.7% from ₹776.08 million. Revenue from operations grew modestly at 1.4% (standalone) and 7.8% (consolidated). The Board recommended a final dividend of ₹2 per share (40% of face value). Statutory auditors issued unmodified opinions. An emphasis of matter was raised regarding Income Tax department demands of ₹626.90 million from search proceedings under sections 132(1) and 133A; the company has filed appeals. A one-time exceptional gain of ₹258.75 million (standalone) was recognized from fair valuation of Apulki Healthcare investment after losing significant influence. New statutory auditors M/s Kirtane & Pandit LLP recommended for FY26-27 to FY30-31.
Strong PAT growth (~30% consolidated) is positive for shareholders, though modest revenue growth may limit upside. The ₹626.90 million tax demand is a contingent liability but management expects no material impact; however, this creates some uncertainty. Dividend provides immediate shareholder return.